SEC Comment Letter for PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — Oct 4, 2016
PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: Oct. 4, 2016 · CIK: 0001095981 · Accession: 0000000000-16-095803
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-34375
Letter
Mail Stop 3030 October 4, 2016 Marc H. Hedrick, MD President and Chief Executive Officer Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121
Re: Cytori Therapeutics, Inc. Form 10 -K for Fiscal Year Ended December 31, 2015 Filed March 11, 2016 File No. 001-34375
Dear Dr. Hedrick :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Amanda Ravitz
Show Raw Text
Mail Stop 3030 October 4, 2016 Marc H. Hedrick, MD President and Chief Executive Officer Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121 Re: Cytori Therapeutics, Inc. Form 10 -K for Fiscal Year Ended December 31, 2015 Filed March 11, 2016 File No. 001-34375 Dear Dr. Hedrick : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Amanda Ravitz Amanda Ravitz Assistant Director Office of Electronics and Machinery cc: Jeremy Hayden, Esq. General Counsel